Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Gallbladder Neoplasms 3Neuroendocrine Tumors 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Glioma 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1TNBC 1Stomatitis 1Stomach Neoplasms 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Sarcoma 1Recurrence 1Parkinsonian Disorders 1Pancreatic Neoplasms 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neoplasms 1

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × TNBC × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡